Phase II single-arm study of first line treatment with gemcitabine and pazopanib in patients with inoperable locally advanced or metastatic biliary tree cancer (cholangiocarcinoma or gallbladder carcinoma)

Trial Profile

Phase II single-arm study of first line treatment with gemcitabine and pazopanib in patients with inoperable locally advanced or metastatic biliary tree cancer (cholangiocarcinoma or gallbladder carcinoma)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Pazopanib (Primary) ; Gemcitabine
  • Indications Cholangiocarcinoma; Gallbladder cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Sep 2017 Planned End Date changed from 1 Jun 2017 to 1 Oct 2019.
    • 20 Sep 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Apr 2019.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top